Protocol Ledger

NCT05256225 · Phase III · ACTIVE NOT RECRUITING

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Interventional Phase III clinical trial protocol NCT05256225 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-16 Enrollment: 360 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05256225
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)360 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05256225
Protocol FieldVerified Registry Value
NCT IdentifierNCT05256225
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment360 participants (ESTIMATED)
Registered Start Date2022-11-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI